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Naturally occurring hepatitis C virus (HCV) subgenomic RNAs have been found in several HCV patients.
These subgenomic deletion mutants, mostly lacking the genes encoding envelope glycoproteins, were found in
both liver and serum, where their relatively high abundance suggests that they are capable of autonomous
replication and can be packaged and secreted in viral particles, presumably harboring the envelope proteins
from wild type virus coinfecting the same cell. We recapitulated some of these natural subgenomic deletions in
the context of the isolate JFH-1 and confirmed these hypotheses in vitro. In Huh-7.5 cells, these deletion-
containing genomes show robust replication and can be efficiently trans-packaged and infect naïve Huh-7.5 cells
when cotransfected with the full-length wild-type J6/JFH genome. The genome structure of these natural
subgenomic deletion mutants was dissected, and the maintenance of both core and NS2 regions was proven to
be significant for efficient replication and trans-packaging. To further explore the requirements needed to
achieve trans-complementation, we provided different combinations of structural proteins in trans. Optimal
trans-complementation was obtained when fragments of the polyprotein encompassing core to p7 or E1 to NS2
were expressed. Finally, we generated a stable helper cell line, constitutively expressing the structural proteins
from core to p7, which efficiently supports trans-complementation of a subgenomic deletion encompassing
amino acids 284 to 732. This cell line can produce and be infected by defective particles, thus representing a
powerful tool to investigate the life cycle and relevance of natural HCV subgenomic deletion mutants in vivo.
Hepatitis C virus (HCV) is an enveloped virus belonging to
the family Flaviviridae. The virus genome is a positive-stranded
RNA of about 9,600 nucleotides, which contains a single open
reading frame (ORF) encoding both structural (core, E1, E2,
and p7) and nonstructural (NS2, NS3, NS4A, NS4B, NS5A,
and NS5B) proteins (47). Two highly conserved untranslated
regions (UTRs) are found at the 5 and 3 ends, which play
critical roles in both viral translation and replication (13,
14, 23).
HCV is estimated to infect 170 million people worldwide (1,
43) and in a high percentage of individuals causes a chronic
liver infection that frequently evolves into an array of diseases,
including cirrhosis (12, 15, 38) and hepatocellular carcinoma
(4, 7, 17, 30, 38, 49).
The HCV RNA-dependent RNA polymerase (NS5B) has a
high frequency of incorrect nucleotide insertions, in the range
of 104 to 105 base substitutions per site, which can result in
the rapid generation of HCV quasispecies (37, 45). Because of
this huge genetic diversity, HCV is currently classified into six
major genotypes and more than 80 subtypes (44). Recombina-
tion may be another mechanism exploited by HCV to increase
genetic diversity: naturally occurring intergenotypic recombi-
nant viruses that often have their recombination points in the
trans-membrane domains of NS2 were recently identified (20,
21, 26, 27, 33, 35).
Recent publications have reported the presence of natural
HCV subgenomic RNAs in serum and liver of infected pa-
tients, mostly containing large in-frame deletions from E1 up
to NS2, always found together with the full-length wild-type
(wt) RNAs (5, 16, 36, 54). These mutant viral genomes persist
for a long time (at least 2 years), and sequence analysis sug-
gests that subgenomic (the predominant species during this
period) and full-length HCV evolve independently (54). The
relative abundance and persistence of such subgenomic RNAs
in vivo suggests that (i) they are capable of autonomous rep-
lication and (ii) they can be packaged and secreted in infec-
tious viral particles, presumably harboring the envelope
proteins from wt virus coinfecting the same cell.
Analysis of the genetic structure of 18 independent sub-
genomic deletion-containing RNAs (5, 16, 36, 54) strongly
suggests that the possibility of recombination and/or deletion is
restricted to specific regions.
As expected, the 5UTR, the 3UTR, and the region coding
from NS3 to NS5B are always conserved, in line with the
notion that these regions are the minimal requirements for
RNA replication. In addition to the regions required for RNA
replication, however, naturally occurring subgenomic HCV
RNA invariably contains an intact core region and the protease
domain of NS2. In fact, the 5 deletion boundary falls between
the codons for amino acid 189 of core and amino acid 4 of E1
in 33% of cases and between the codons for amino acids 21 and
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29 of E1 in 39% of cases, such that in 72% of cases overall, the
5 boundary is between the codons for amino acid 189 of core
and amino acid 29 of E1 (see Fig. S1 in the supplemental
material). Likewise, the 3 boundary shows a distinct localiza-
tion, occurring between the codons for amino acids 51 and 79
of NS2 in 56% of cases.
In the present study, we modified the infectious isolate
JFH-1 in order to recapitulate in vitro the genetic structure of
two of the most representative in-frame natural subgenomic
deletion-containing RNAs found circulating in patients (28, 51,
57). Using this system, we analyzed natural subgenomic vari-
ants for their ability to replicate autonomously and demon-
strated that the natural subgenomic deletion mutants are rep-
lication competent and are trans-packaged into infectious
virions when coexpressed together with wt virus. Furthermore,
our data suggest that the presence of the NS2 protease domain
is required in order to generate the correct NS3 N terminus,
required for RNA replication. Unexpectedly, the presence of
NS2 generates, in turn, a strict cis requirement for the core
region in order to allow efficient trans-packaging of the sub-
genomic RNA, revealing a complex interplay between the NS2
and the core viral genes. Finally, we performed trans-comple-
mentation studies of the subgenomic deletions with different
HCV structural proteins to gain insight into the minimal re-
quirements for the assembly and release of HCV virions.
MATERIALS AND METHODS
Cell lines and culture conditions. The human hepatoma-derived cell line
Huh-7.5 (6) was grown in high-glucose Dulbecco’s modified Eagle medium
(DMEM; Life Technologies) supplemented with 2 mM L-glutamine, 100 U/ml of
penicillin, 100 g/ml of streptomycin, and 10% fetal bovine serum. A stable cell
line expressing the region core-p7 was generated by transfection with 2.5 g of
pEF6/V5-core-p7 plasmid in Huh-7.5 cells that were subsequently cultured in the
presence of 3 g/ml of blasticidin S HCl (Invitrogen). Blasticidin S-resistant
clones were isolated and expanded. Clone 9 was selected following immunostain-
ing with anticore antibody and a functional assay. Cells were subcultivated twice
per week, with a 1:4 split ratio.
Manipulation of nucleic acids and construction of recombinant plasmids.
Nucleic acids were manipulated according to standard protocols, and plasmid
DNA was prepared from overnight cultures in Luria-Bertani broth using the
CsCl method (41). Deletions mutants were constructed in the context of the
J6/JFH chimera using a PCR-based strategy and employing the following
oligonucleotides: for J6/JFH-284–736, E1-p7rev (5-GATGAGCATCCAT
AAGCAGGCGCACATCACCCCACCGCAGAGGT-3) and E1-p7for (5-A
CCTCTGCGGTGGGGTGATGTGCGCCTGCTTATGGATGCTCATC
-3); for J6/JFH-212–890, 212-886rev (5-GCCAAGAGCCACTTGGTTAT
GTCAAAACCAATGCTGTCATTGGTGCAGTCGTTAGT-3) and 212-
886for (5-ACTAACGACTGCACCAATGACAGCATTGGTTTTGACATA
ACCAAGTGGCTCTTGGC-3); for J6/JFH-E1E2, 217-567for (5-GACT
GCACCAATGACAGCATTACCTGGCAGCTCGCACCACCCTGCCGTA
CTAGAGCTGACT-3) and 217-567rev (5-AGTCAGCTCTGATACGGCA
GGGTGGTGCGAGCTGCCAGGTAATGCTGTCATTGGTGCAGT-3).
Expression plasmids were constructed by using a PCR-based strategy and
employing the appropriate oligonucleotides for cloning in the pEF6/V5His
TOPO expression vector (Invitrogen). For core-NS2, Core2afor (5-ACCATG
AGCACAAATCCTAAACCT-3) and NS22arev (5-CTAGAGAAGACTCCA
CCCCTTGGA-3); for core-p7, Core2afor and p72arev (5-CTAAGCATAAG
CCTGTTGGGGCAA-3); for core-E2, Core2afor and E2Stop (5-CTATGCT
TCGGCCTGGCCCAACAAGATGAGCATCCATAAGCA-3); for spE1-NS2,
spCoreATG (5-ACCATGGCAACAGGGAACTTACCCGGTTGCTCCTTTT
CTATCT-3) and NS2-2arev; for spE1-p7, spCoreATG and p72arev; for spE1-
E2, spCoreATG and E2Stop.
Subgenomic deletions containing luciferase reporter gene followed by the 2A
protease of foot-and-mouth disease virus (FMDV) or ubiquitin monomer (UBI)
were constructed by using a PCR-based strategy and employing the following oli-
gonucleotides: LUC-UBI-DIR (5-GCCAAGAAGGGCGGAAAGATCGCCGT
GATGCAGATCTTCGTGAAGACCCTGACG-3), LUC-UBI-REV (5-CGTCA
GGGTCTTCACGAAGATCTGCATCACGGCGATCTTTCCGCCCTTCTTGG
C-3), UBI-NS3-DIR (5-GCACCTGGTGCTGCGTCTCCGCGGTGGTGCTCC
CATCACTGCTTATGCCCAGCAA-3), UBI-NS3-REV (5-TTGCTGGGCATA
AGCAGTGATGGGAGCACCACCGCGGAGACGCAGCACCAGGTG
C-3), UBI-NS2-Dir (5-GCACCTGGTGCTGCGTCTCCGCGGTGGTTATGAC
GCATCTGTGCATGGCCAGATA-3), UBI-NS2-REV (5-TATCTGGCCATGC
ACAGATGCGTCATAACCACCGCGGAGACGCAGCACCAGGTG
C-3), LUC-2A-NS2Dir (5-AGCTGGCCGGCGACGTGGAAAGCAACCCAG
GCCCATATGACGCATCTGTGCATGGCCAGAT-3), LUC-2A-NS2REV (5-
TTCCACGTCGCCGGCCAGCTTCAGCAGGTCGAAGTTCAGCAGCTGCA
CGGCGATCTTTCCGCCCTTCTTGGC-3), core-luc-dir (5-GAAAAACCAAA
AGAAACACCAACCGTCGCCCAATGGAAGACGCCAAAAACATAAAGG
AAG-3), core-luc-REV (5-CTTCCTTTATGTTTTTGGCGTCTTCCATTGGG
CGACGGTTGGTGTTTCTTTTGGTTTTTC-3), 212E1-luc-dir (5-TAACGACT
GCACCAATGACAGCATTATGGAAGACGCCAAAAACATAAAGGAAGG
C-3), and 212E1-luc-REV (5-GCCTTCCTTTATGTTTTTGGCGTCTTCCATA
ATGCTGTCATTGGTGCAGTCGTTA-3). The firefly luciferase gene was origi-
nally cloned from pGL2 vector (Promega).
FMDV2A (60 nucleotides, corresponding to the 19-amino-acid sequence QLLN
FDLLKLAGDVESNPGP) and a UBI monomer DNA fragment (228 nucleotides,
corresponding to the 76-amino-acid sequence MQIFVKTLTGKTITLEVEPSDTI
ENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRL
RGG) were assembled in vitro with small oligonucleotides. All the PCR-amplified
fragments and final constructs were verified by sequencing.
In vitro transcription and electroporation. Plasmid DNAs encoding full-
length HCV and HCV with subgenomic deletions were linearized with XbaI and
transcribed in vitro by T7 RNA polymerase using an Ambion Megascript kit
under nuclease-free conditions following the manufacturer’s instructions. Tran-
scription mixtures were treated with DNase I (except for cotransfections with
DNA plasmid) and purified on Microspin G25 columns (GE Healthcare) ac-
cording to the manufacturer’s instructions. RNA eluted in nuclease-free water
was quantified by measurement of the optical density at 260 nm, immediately
frozen in dry ice, and stored at 80°C. Denaturing gel electrophoresis was used
to check RNA integrity.
For electroporation of HCV RNA, confluent cells from 15-cm-diameter plates
were split 1:2, and after 20 h, cells were recovered in 5 ml medium, washed twice
with DMEM (Life Technologies), filtered with Cell Strainer filters (Falcon), and
diluted in diethyl pyrocarbonate-treated phosphate-buffered saline (PBS) at a
concentration of 107 cells/ml. The appropriate amount of RNA was mixed with
200 l of cell suspension and then electroporated using a Bio-Rad Genepulser II
in a cuvette with a gap width of 0.2 cm (Bio-Rad), with two pulses at 25 F and
0.4 V. For cotransfections of wt J6/JFH and virus with subgenomic deletions, 3
g of each RNA was used. For RNA and DNA cotransfections, 3 g deletion
mutants or replicon RNA plus 1.5 g structural protein DNA were used. Im-
mediately after electric pulses, cells were incubated for 10 min at 37°C, diluted
in complete DMEM, and plated.
Replication and infection assays. For replication assays, transfected cells were
plated on 96-well-plates at 105, 6.6  104, 5  104, and 3.3  104 cells/well, for
24, 48, 72, and 120 h, respectively, accordingly to the time frame of the assay.
Cellular RNA was purified with a 96-well total RNA isolation kit (Applied
Biosystems) on a Starlet workstation (Hamilton) following the manufacturer’s
instructions. RNA eluted in nuclease-free water was quantified by measurement
of the optical density at 260 nm, and denaturing gel electrophoresis was used to
check RNA integrity.
For the infection assay, 50 l of the relevant supernatant was transferred onto
6  103 naïve Huh-7.5 or clone 9 cells plated in a 96-well-plate in 50 l of
complete DMEM. After 2 days, total RNA was extracted, or cells were fixed for
the immunostaining assay. Polyclonal antibody -CD81 (clone 1.3.3.22; Santa
Cruz Biotechnology) at 1 g/ml was used to inhibit infection, while NS3 protease
inhibitor (PI) at 1 M was used to inhibit replication (29).
Quantitative detection of HCV RNA and luciferase assay. The number of HCV
genomes was determined by quantitative PCR (qPCR) TaqMan assay. Briefly, a
384-well-plate-based assay was performed with 10 to 50 ng of total RNA per well. To
quantify HCV in RNA samples, the following oligonucleotides and probe sets were
used: HCV-IRES (general set that recognize all constructs), sense (5-GCGAAAG
GCCTTGTGGTACT-3), antisense (5-CACGGTCTACGAGACCTCCC-3),
and probe (5-CCTGATAGGGTGCTTGCGAGTGCC-3, 5 6-carboxyfluorescein
[FAM]/3 6-carboxytetramethylrhodamine [TAMRA]); J6/JFH-212–890 specific,
sense (5-TGCCGAAGTGAAGAACATCAGT-3), antisense (5-AGCCACTTG
GTTATGTCAAAACC-3), and probe (5-CGGCTACATGGTGACTAACGACT
GCACC-3, 5 FAM/3 TAMRA); J6/JFH-284–736 specific, sense (5-CGGTGG
GGTGATGTGCG-3), antisense (5-GCGTGCAAGATGACCAGCTT-3), and
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probe (5-TCATCTTGTTGGGCCAGGCCGA-3, 5FAM/3TAMRA); J6/JFH-
E1E2 specific, sense (5-TGCCGAAGTGAAGAACATCAGT-3), antisense (5-
GGTGCGAGCTGCCAGGTA-3), and probe (5-TGACTAACGACTGCACCA
ATGACAGC-3, 5FAM/3TAMRA); full-length J6/JFH specific, sense (5-CACA
GCTTCAACTCGTCAGGAT-3), antisense (5-ACCCGGAAGGCCTCGATAC-
3), and probe (5-TCCCGAACGCATGTCCGCC-3, 5 FAM/3 TAMRA); JFH-
neo-replicon specific (neomycin), sense (5-GATGGATTGCACGCAGGTT-3),
antisense (5-GCCCAGTCATAGCCGAATAGC-3), and probe (5-TCCGGCCG
CTTGGGTGGAG, 5 FAM/3 TAMRA). The primers and the probe were used at
0.9 pmol and 0.25 pmol, respectively, per 20-l reaction mixture. All reactions were
run in triplicate with ABI PRISM 7900 (Applied Biosystems) under the following
conditions: 30 min at 50°C (reverse transcriptase step), 10 min at 95°C, 40 cycles of
15 s at 95°C and 1 min at 60°C. Quantitative calculations were obtained either using
the comparative cycle threshold method (described in user bulletin 2 of the ABI
PRISM 7700 sequence detection system; Applied Biosystems, December 1997) with
the level of rRNA (rRNA 18S mix; Applied Biosystems) or by quantification with an
appropriate transcript-specific RNA titration curve. Quantification of rRNA was
used for normalization of HCV genome copies that were expressed per 50 ng of total
RNA. The luciferase assay was performed with a Bright-Glo luciferase assay system
(Promega) following the manufacturer’s instructions.
Transfections in wt J6/JFH-infected Huh-7.5 cells. Huh-7.5 cells transfected
with the wt J6/JFH transcript (10 g RNA) were cultured for 6 days, mixed 1:1
with naïve Huh-7.5 cells, cultured for an additional 6 days, and finally transfected
again with 5 g of subgenomic deletion mutants.
Immunostaining. Cells were fixed for 20 min with ice-cold isopropanol,
washed three times with PBS, blocked with 5% nonfat dry milk in PBSTS (PBS,
0.1% Triton X-100, and 0.02% sodium dodecyl sulfate), and incubated overnight
at 4°C with a monoclonal anticore (mouse anti-HCV core antigen immunoglob-
ulin G [IgG] fraction, clone 4H2-2; Austral Biologicals) or anti-NS5A (mouse
anti-HCV NS5 antigen IgG fraction, clone 2F6/G11; Austral Biologicals) diluted
in milk-PBSTS. After five washes with PBSTS, cells were incubated for 3 h at
room temperature with anti-human IgG conjugated to alkaline phosphatase
(Sigma) in milk-PBSTS. After five more washes with PBSTS and one with PBS,
bound antibodies were revealed with the alkaline phosphatase substrates p-
nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolylphosphate. Foci
were counted, and the results are the averages from four wells.
RESULTS
Generation of J6/JFH deletion mutants. For our study, we
selected two representative natural subgenomic deletions (36):
284–732 (corresponding to 284–736 in JFH-1, due to a
4-amino-acid insertion in E2 in this isolate), resulting in an
in-frame 448-amino-acid deletion spanning E1 and E2 (from
amino acid 284 in E1 to amino acid 732 in E2), and 212–886
(corresponding to 212–890 in JFH-1), resulting in an in-
frame 674-amino-acid deletion from position 212 in E1 to
amino acid 886 in NS2. While the former deletion spans the
coding regions of E1 and E2, the latter completely removes E2
and p7. We generated these deletions in the J6/JFH back-
ground (J6/JFH-284–736 and J6/JFH-212–890 [Fig. 1]),
since it efficiently supports both replication and virus produc-
tion in Huh-7.5 cells (28). Of note, the NS2 boundary (amino
acid 890) in J6/JFH-212–890 is located at the junction be-
tween the membrane-spanning and protease domains of NS2
FIG. 1. Schematic representation of subgenomic HCV RNAs used in this study. The 5 NTR, 3 NTR, and EMCV IRES (solid line) structures
are shown, and ORFs are depicted as open boxes with the polyprotein cleavage products indicated. Parental (wt) J6/JFH genome (encoding amino
acids 1 to 1030 [J6] and 1031 to 3034 [JFH1]) is shown on top, and the JFH-1 replicon (JFH-neo-rep) is at the bottom.
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(55), more exactly inside the third trans-membrane domain and
downstream of the C4 junction (amino acid 876), reported to
be important for efficient generation of intra- and intergeno-
typic HCV chimeras (40). According to the hypothesized to-
pology of NS2 (55), this deletion has a defective NS2 that
cannot be membrane associated and is impaired for virus pro-
duction, as already shown by Jirasko and coworkers (18). We
also generated the deletion mutant J6/JFH-E1E2 (deletion
from the codon for amino acid 217 in E1 to that for amino acid
567 in E2), previously used as a nonpackaging control RNA
transcript (3, 40, 42, 51).
J6/JFH subgenomes replicate efficiently in human hepa-
toma Huh-7.5 cells. RNA transcripts harboring the sub-
genomic deletions J6/JFH-284–736 and J6/JFH-212–890
were transfected into naïve Huh-7.5 cells to verify whether
they were replication competent. J6/JFH-E1E2 and wt J6/
JFH were used as controls. Total cellular RNA was extracted
at 24, 48, 72, and 120 h posttransfection (p.t.), and qPCR was
performed to measure the number of RNA copies. The results
demonstrate that subgenomic deletion mutants are replication
competent but with slightly different profiles (Fig. 2).
J6/JFH-212–890 and J6/JFH-284–736 replicate more ef-
ficiently than the wt construct at 24 h p.t., with a peak at 48 h
followed by a rapid decline, to the extent that RNA cannot be
detected at 120 h p.t. This might reflect a cytotoxic effect due
to the accumulation of core protein and/or replication com-
plexes in the cells (42). A similar replication profile is observed
with J6/JFH-E1E2, although with lower efficiency. J6/JFH, as
expected, showed a steady progression, starting moderately
low at 24 h and increasing considerably at 5 days due to effi-
cient virus production and spreading, as demonstrated by as-
saying supernatant for infection (data not shown). As ex-
pected, all the subgenomic deletion mutants behaved as bona
fide replicon units but lacked the ability to produce infectious
particles (see Fig. 10; also data not shown).
Subgenomic deletion mutants are trans-packaged in Huh-
7.5 cells infected with wt J6/JFH virus. Having demonstrated
that the naturally occurring HCV subgenomes are capable of
autonomous replication in Huh-7.5 cells, we investigated
whether they could be packaged into infectious virions in the
presence of the wt virus.
With this aim, we transfected Huh-7.5 cells with J6/JFH
RNA and passaged cells for 9 days, a time sufficient to obtain
approximately 100% infected cells (57). These cells were sub-
sequently transfected with subgenomic deletion mutants and
replicon (JFH-neo-rep) RNA transcripts (22). Supernatants
from each transfection were collected at 24, 48, and 72 h p.t.
and transferred onto naïve Huh-7.5 cells for an infection assay.
After 2 days, total cellular RNA was extracted and analyzed by
real-time qPCR. In order to identify the different constructs,
we used specific sets of qPCR probes that enabled us to quan-
tify precisely each different RNA genome.
Figure 3A shows the specific J6/JFH wt RNA quantification in
cells infected with the different supernatants. As expected, we
observed that similar amounts of wt J6/JFH virus were present in
all the supernatants from the different transfection experiments.
The observed decline of J6/JFH in the supernatant collected 72 h
p.t. probably resulted from the competition of replication and
packaging factors between the two transfected genomes. Quanti-
fication of each individual deletion construct in the corresponding
transfection (Fig. 3B) showed that both the subgenomic deletion
mutants and JFH-neo-rep were trans-packaged and, upon release
in the supernatants, were able to infect naïve Huh-7.5. It is worth
noting that J6/JFH-212–890, which is defective in NS2, could be
trans-complemented not only by wt E1, E2, and p7 but also by wt
NS2 expressed by wt J6/JFH. In all cases, replication and bona
FIG. 2. Replication efficiency of subgenomic deletion mutants in Huh-7.5 cells. RNA transcripts were transfected into Huh-7.5 cells, and total
cellular RNA was extracted at different times from 24 to 120 h p.t. RNA was quantified by qPCR utilizing rRNA for normalization. Values are
medians from at least three independent experiments. Error bars indicate standard deviations.
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fide infection were demonstrated by the efficacy of a replication
inhibitor (an NS3 PI) (Fig. 3) and by treatment with an anti-CD81
monoclonal antibody (data not shown), respectively.
The ratio between packaged subgenomic deletion mutants
and wt J6/JFH RNA was very low, about 1:40 (on average, 4 
106 copies of J6/JFH and 1  105 copies of subgenomic dele-
tion mutants per 50 ng of total RNA). As expected, with the
exception of wt J6/JFH, the second passage of supernatants
FIG. 3. trans-packaging efficiency of subgenomic deletion mutants in Huh-7.5 infected with wt J6/JFH. Subgenomic deletion mutants and JFH-1
replicon (JFH-neo-rep) RNA were transfected into J6/JFH-infected Huh-7.5 cells. Supernatants of each transfection experiment were collected
at 24, 48, and 72 h p.t. and used to infect naïve Huh-7.5 cells. Total cellular RNA was extracted at 48 h postinfection, and RNA quantification was
performed by quantitative qPCR with J6/JFH (A) or individual subgenome-specific (B) oligonucleotide-probe sets. Quantification of rRNA was
used for normalization, and values are numbers of HCV genome copies per 50 ng of total RNA. Values are medians from at least three
independent experiments. Error bars indicate standard deviations.
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onto naïve Huh-7.5 cells resulted in no productive infection,
presumably due to the small chance of coinfection of a single
naïve cell with wt and deletion-containing genome virus. In
evaluating the results, we should consider the possibility that
they might have been negatively affected by many factors, such
as efficiency of transfection in the infected cells, interference
with or competition of the transfected RNA by the resident wt
genome, and replication efficiency of each subgenomic dele-
tion. Altogether, these results demonstrate that subgenome
deletion mutants can be trans-packaged in cell culture by a wt
virus.
Subgenomic deletion mutants are efficiently trans-packaged
when cotransfected with wt J6/JFH RNA into Huh-7.5 cells.
Next, we decided to explore whether cotransfection of the
deletion-containing genomes with wt J6/JFH RNA could result
in their trans-packaging. This experimental setting would allow
us to better quantify the relative replication and packaging
efficiencies of the different RNA genomes. Thus, naïve Huh-
7.5 cells were cotransfected with equal amounts of wt J6/JFH
and individual subgenomic RNA (3 g), and supernatants
were collected at 24, 48, and 72 h p.t. and transferred onto
naïve Huh-7.5 cells for a 2-day infection assay. Cellular RNA
was then extracted and analyzed by qPCR to monitor genome
replication as a consequence of infection.
As shown in Fig. 4A, in all cases we could measure the
infection of J6/JFH-wt virus. As expected, the number of HCV
copies increased over time due to the virus spreading. Consid-
erable differences appeared when the infection of packaged
subgenomic deletion mutants was measured. The deletion mu-
tant most efficient in trans-packaging was J6/JFH-212–890,
whose amount was 3- and 1.6-fold higher than that of the wt
J6/JFH at 24 and 48 h, respectively, followed by J6/JFH-284–
736 (1.3- and 0.4-fold) and J6/JFH-E1E2 (0.6- and 0.2-fold)
(Fig. 4B). Though measurable, the signal of the trans-packaged
JFH-neo-rep was very poor compared to signals of the other
subgenomic deletion mutants, being only 0.1- and 0.08-fold
that of the wt genome at 24 and 48 h, respectively. Replication
and infection were confirmed by treating the cells with a PI and
an anti-CD81 monoclonal antibody, respectively.
It is worth noting that in the cotransfection experiments, the
RNAs corresponding to the natural subgenomic deletion mu-
tants were more efficiently trans-packaged than the in-house-
generated J6/JFH-E1E2 RNA. This might suggest that in
vivo, selection of HCV subgenomic RNA follows the evolu-
tionary rule of survival of the fittest. It is conceivable that
natural subgenomic deletion mutants sustain the competition
of wt virus for both replication and packaging, thereby achiev-
ing efficient spreading and stability in patients.
Core and NS2 contribute to replication and trans-packaging
efficiency. In order to determine the contributions of core and
NS2 to both replication and trans-packaging efficiency of sub-
genomic deletion mutants, we generated the constructs de-
picted in Fig. 5 in which the core-E1 and/or NS2 coding se-
quences was selectively removed. To facilitate the detection of
replication and infection, a firefly luciferase reporter gene was
inserted upstream of NS2 or NS3, separated by the FMDV2A
autoprotease (9) or a UBI monomer (6, 39) in order to guar-
antee the correct processing of their N termini. We were un-
able to generate replication-competent constructs with
FMDV2A autoprotease located upstream of NS3, likely due to
the incorrect generation of the NS3 N terminus. These con-
structs were individually tested for replication efficiency in
naïve Huh-7.5 cells. After RNA transfection, luciferase activity
was measured at 5, 24, 48, and 72 h (Fig. 6). Although the same
amount of RNA was transfected for all constructs, luciferase
readings at 5 h (measuring transient translation of the trans-
fected RNA) were substantially different. Constructs contain-
ing the core coding region (namely, Luc-core212-NS2 and
Luc-core212-NS3) showed a lower luciferase signal than
those without the core region. The same results were obtained
in many independent experiments, and it is therefore conceiv-
able that the differences observed do reflect different transla-
tion efficiencies of the various constructs rather than simply
different transfection efficiencies. This finding is not surprising,
given that the core region has been suggested to negatively
influence internal ribosome entry site (IRES)-dependent
translation (8, 52, 56).
After a sharp decline at 24 h p.t., the luciferase signal asso-
ciated with cells transduced with Luc-core212-NS2, Luc-no-
core-NS2, and Luc-nocore-NS3 increased to levels higher than
those observed at 5 h p.t., indicating amplification of the trans-
fected RNA. Replication of the RNA constructs at 72 h was
confirmed by the inhibitory effect of an NS3 PI (Fig. 6A).
Unexpectedly, Luc-core212-NS3 failed to replicate. Accord-
ing to the relative luciferase signals, at 72 h p.t., the Luc-
core212-NS2 RNA was amplified 8.3-fold compared to the
5-h reading. Conversely, for the two constructs lacking the core
region, namely, Luc-nocore-NS2 and Luc-nocore-NS3, the lu-
ciferase signals at 72 h p.t. were 0.7- and 3.3-fold higher than
the 5-h measurement. These data suggest that the presence of
the core sequence could positively affect the replication capa-
bility of a subgenomic HCV RNA. To assess the potential of
the same constructs to be trans-packaged by the wt helper
virus, we cotransfected them with equal amounts of wt J6/JFH
RNA into Huh-7.5 cells. After 48 h we collected the superna-
tants and transferred these onto naïve Huh-7.5 cells for a 2-day
infection assay. As expected, no infectious particles were pro-
duced without cotransfection with J6/JFH (Fig. 7). Conversely,
when cotransfected with J6/JFH, only Luc-core212-NS2 and
Luc-nocore-NS3 were able to be trans-packaged by J6/JFH.
Interestingly, these constructs either have both core and NS2
or have neither. In contrast, construct Luc-nocore-NS2, which
showed a good replication capability, was not able to be trans-
packaged efficiently. Finally, Luc-core212-NS3 was unable to
replicate (even in the presence of wt J6/JFH) and consequently
to be trans-packaged. In conclusion, these data reveal a com-
plex interplay between the core region and the NS2 regions in
the regulation of trans-packaging and possibly RNA replica-
tion.
Cloning of structural proteins into an expression vector and
trans-complementation of subgenomes. In order to elucidate
whether trans-packaging of subgenomes could also be achieved
by providing structural proteins outside the context of a repli-
cating wt virus, we cloned them into a plasmid DNA expression
vector (pEF6/V5; Invitrogen). This approach also gave us the
opportunity to analyze in detail the minimal requirements for
efficient trans-packaging. With this aim, we cloned the coding
region from core to NS2, in various arrangements (Fig. 8). In
the constructs lacking core, correct expression and localization
of E1-E2 structural proteins was achieved by including the
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terminal region of core protein (27 amino acids) as a signal
peptide (10, 11).
We tested the ability of these constructs to trans-package
different subgenomic deletion mutants by DNA-RNA cotrans-
fections in hepatoma cells. After cotransfection of the expres-
sion plasmids and subgenomic RNA transcripts in Huh-7.5
cells, supernatants were collected at different times and ap-
plied to naïve Huh-7.5 cells for a 2-day infection followed by
immunostaining using an anticore antibody (or anti NS5A in
the case of JFH-neo-rep) in order to estimate the amount of
infected cells. Bona fide infection versus passage of naked (or
complexed) RNA was guaranteed by the lack of positive cells
when infection was performed in the presence of anti-CD81.
Representative results obtained with supernatants collected at
48 h p.t. are summarized in Fig. 8.
Among all the cotransfections performed, some were not
FIG. 4. Efficiency of packaging of subgenomic deletion mutants and JFH-1 replicon when cotransfected with wt J6/JFH RNA. Subgenomic
deletion mutants or the JFH-1 replicon (JFH-neo-rep) was cotransfected (3 g RNA each per 2  106 cells) into Huh-7.5 cells with an equal
amount of wt J6/JFH RNA. Supernatants of each transfection were collected at 24, 48, and 72 h p.t. and used to infect naïve Huh-7.5 cells. Total
cellular RNA was extracted at 48 h, and RNA of different genomes was quantified by quantitative qPCR with construct-specific oligonucleotide-
probe sets. Quantification of rRNA was used for normalization, and HCV RNA amounts are expressed as number of genome copies per 50 ng
of total RNA. (A) Results of the infection with supernatants collected at the indicated times p.t. Values are medians from at least three
independent experiments. Error bars indicate standard deviations. (B) Ratio of the copy number of subgenomic deletion mutants to that of J6/JFH
RNA.
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expected to produce viral particles. This concerned all the
cases in which parts of the HCV coding regions were missing
both in the genome RNAs and in the vectors expressing the
structural proteins. On this basis, JFH-neo-rep could in theory
be trans-packaged only with core-NS2 (the only construct we
tested) and J6/JFH-212–890, which lacks p7 and the trans-
membrane domain of NS2, only with core-NS2 and spE1-NS2.
The results obtained, besides confirming some of these predic-
tions, revealed some additional interesting findings. In fact,
core-NS2, which spans all structural proteins from core to the
whole NS2, was not able to trans-package any of the sub-
genomic deletion mutants or JFH-neo-rep.
Interestingly, exclusion of NS2, as in the case of core-p7,
efficiently confers complementation capacity to the expressed
proteins with both subgenomic deletion mutants J6/JFH-
284–736 and J6/JFH-E1E2, the former being more effi-
ciently trans-packaged. Furthermore, when the core-coding
region was excluded, as in spE1-NS2, J6/JFH-E1E2, J6/JFH-
284–736, and J6/JFH-212–890 were all trans-packaged.
Again, it is worth noting that infectivity of the NS2-defective
mutant J6/JFH-212–890 was rescued by the expression of wt
NS2 (namely, spE1-NS2).
Together with these results, the observation that core-NS2 is
also not able to trans-complement any subgenomic deletion
mutants (J6/JFH-E1E2, J6/JFH-284–736, or J6/JFH-212–
890) suggests that the presence of both core and NS2 in the
expression vector does not lead to productive trans-packaging.
It is sufficient to exclude one of the two, however, to restore
this capability. These results suggest that the mechanism un-
derlying trans-complementation of subgenomic deletions with
wt virus (J6/JFH) is different from that achieved by simply
providing structural proteins with an expression vector which is
thus outside the viral context.
A stable cell line expressing core-p7 structural proteins sup-
ports both trans-packaging of deletion-containing RNA ge-
nomes and spreading of the defective virus. The possibility of
complementing subgenomic deletions with structural proteins
expressed in trans prompted us to explore whether a stable cell
line supporting multiple rounds of infection by defective par-
ticles containing subgenomic deletions could be generated.
Taking advantage of the presence of the blasticidin resis-
tance gene in the expression vector described above, we se-
lected a cell line, clone 9, stably expressing core-p7. We then
tested this clone for the capacity to trans-complement the
packaging of J6/JFH-284–736 and J6/JFH-E1E2.
If clone 9 were to prove capable of trans-packaging sub-
genomic RNA and of being infected, a full cycle of virus pro-
duction and infection could be established, allowing defective
virus to be spread. In addition, the release of virus particles
might also reduce the toxicity derived from accumulation of
viral proteins, such as core (see above). Taking all these hy-
potheses together, by transfecting subgenomes in clone 9, we
expected to obtain replication profiles similar to those ob-
tained by transfecting J6/JFH in naïve Huh-7.5.
FIG. 5. Schematic representation of subgenomic HCV mutants expressing a luciferase reporter gene. The 5 NTR, 3 NTR, and EMCV IRES
(solid line) structures are shown, and ORFs are depicted as open boxes with the polyprotein cleavage products indicated. The luciferase-2A
reporter gene was inserted after the codons for amino acid 212 of E1 and amino acid 19 of core in Luc-core212-NS2 and Luc-nocore-NS2,
respectively, and before the codon for amino acid 814 of NS2 in both. The luciferase-UBI reporter gene was inserted after the codons for amino
acid 212 of E1 and amino acid 19 of core in Luc-core212-NS3 and Luc-nocore-NS3, respectively, and before the codon for amino acid 1031 of
NS3 in both.
9086 PACINI ET AL. J. VIROL.
 o
n
 April 2, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
RNA transcripts of the subgenomic deletion mutants J6/
JFH-284–736, J6/JFH-E1E2, and wt J6/JFH were trans-
fected into both Huh-7.5 and clone 9 cells. A large amount (10
g) of RNA was used to achieve maximal replication and
packaging. RNA replication was followed by real-time qPCR
at 24, 48, and 72 h p.t.
As predicted (and shown in Fig. 2), in Huh-7.5 cells, the
subgenomic deletion mutants J6/JFH-284–736 and J6/JFH-
E1E2 replicated efficiently starting as early as at 24 h, peaking
at 48 h, and declining rapidly thereafter, while wt J6/JFH
increased constantly (Fig. 9). However, the transfection of
clone 9 showed different kinetics. In this case, J6/JFH-284–
736 and J6/JFH-E1E2 RNA levels also steadily increased
with time, clearly demonstrating that the signal was more than
the result of simple replication and likely involved production
and reinfection of defective particles.
In addition to monitoring RNA replication, we collected
supernatants of each transfection at 2 days p.t., at which time
a sufficient amount of virus particle production had been ob-
served in previous experiments. Each supernatant was trans-
FIG. 6. Replication of subgenomic deletion mutants expressing a luciferase reporter gene. RNA transcripts were transfected into Huh-7.5 cells,
and luciferase activity was measured at different times from 5 to 72 h p.t. Values are medians from at least three independent experiments. Error
bars indicate standard deviations. (A) Efficiency of replication of each RNA, measured in luciferase units. (B) Results from panel A, reported as
percentages of the value at 5 h for each RNA.
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ferred onto naïve Huh-7.5 (Fig. 10A) and clone 9 (Fig. 10B)
cells, and HCV replication and infection at 1, 2, and 3 days
postinfection were monitored by real-time PCR. As shown in
Fig. 10, with the exception of J6/JFH-284–736 and J6/JFH-
E1E2 transfection into naïve Huh-7.5 cells, we observed in-
fection by all supernatants, demonstrating that clone 9 pro-
duces defective particles and therefore behaves exactly as
predicted. In all cases, anti-CD81 and PI completely abolished
any signal, demonstrating that the signals measured derived
from infection.
FIG. 7. trans-packaging of subgenomic deletion mutants expressing a luciferase reporter gene. Subgenomic deletion mutants containing a
luciferase reporter were cotransfected (3 g RNA each per 2  106 cells) in Huh-7.5 cells alone or with equal amounts of wt J6/JFH RNA.
Transfection supernatants were collected at 48 h p.t. and used to infect naive Huh-7.5 cells. Luciferase activities of each infection were measured
at 48 h postinfection. Values are medians from at least three independent experiments. Error bars indicate standard deviations.
FIG. 8. Summary of naïve Huh-7.5 infections with supernatants generated by DNA-RNA cotransfections of subgenomic deletion mutants with
structural protein expression vectors at 48 h p.t. Subgenomic deletion mutants used in the cotransfection experiments are at the tops of the
columns, and expression vectors are on the left. The qualitative evaluation of packaging efficiency is proportionally expressed with plus signs.
Numbers in parentheses are the numbers of foci (two to four cells each) detected by immunostaining. The results are the averages from four
independent experiments. n.t., not tested.
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Similarly to transfection of naked RNA, the time-dependent
increasing signal in clone 9 transfected with deletion mutants
strongly suggests that clone 9 was able to support production,
as well as spreading, of the defective virus particles. This was
confirmed by the observation that by immunostaining with
anticore antibody, single infected cells were seen in Huh-7.5
while groups of infected cells were visible in clone 9 (data not
shown).
Altogether, these experiments demonstrate that clone 9 sup-
ports virus production from a transfected subgenomic HCV
RNA, and this defective virus is capable of spreading in this
cell line. Thus, clone 9 can be considered a helper cell line. It
is noteworthy that this defective virus is still capable of infect-
ing naïve Huh-7.5 cells, and the RNA replicates inside the
infected cells but is not able to produce viruses.
DISCUSSION
In this study, we attempted to elucidate the poorly under-
stood phenomenon of the presence of HCV deletion mutants
circulating in chronically infected patients (36), liver transplant
recipients (16), and patients with immunosilent infections (5).
To date, the clinical relevance of these naturally occurring
subgenomic deletion mutants has not been clarified. A con-
stant feature of such deletion mutants is that they are present
in large amounts both in serum and in liver, where the ratio
between deletion-containing genomes and wt could be as high
as 500:1 (54). This probably depends on subgenomes having to
compete with the wt virus for replication space inside the
hepatic cell, which, combined with the dependence on wt for
trans-packaging, might have restricted the size and boundary of
the deletions.
It is noteworthy that in almost all subgenomic deletion mu-
tants reported (5, 16, 36, 54), the integrity of the core protein
is maintained, as are some amino acid sequences of E1 that
might be necessary for the correct core processing. We cannot
exclude the possibility that this could merely increase the
amount of core protein in the host cell, thus increasing the
chance of subgenome trans-packaging, but our results suggest
that the conservation of this region might have additional sig-
nificance.
The idea that the core region contains some important RNA
structures has already been explored. In attempt to elucidate
the role of the core alternative reading frame, McMullan and
coworkers found that when an H77 RNA transcript containing
mutations that destroyed two RNA structures (stem-loops V
and VI) in the core region was inoculated into a chimpanzee,
this gave rise to an atypical attenuated infection (31). After a
few weeks, mutations in stem-loop VI reverted to wt, suggest-
ing that this structure plays an important role in the HCV life
cycle (31). Very recently, another study reached analogous
conclusions with the JFH-1 isolate, also determining the im-
portance of other RNA structures in the same region that play
important roles in translating the genome and are required for
robust viral production both in vitro and in vivo (50). Also in
FIG. 9. Efficiency of replication of J6/JFH-284–736, J6/JFH-E1E2, and J6/JFH in naïve Huh-7.5 and clone 9 cells. RNA transcripts were
transfected (10 g RNA per 2  106 cells) in naïve Huh-7.5 and clone 9 cells, and total cellular RNA was extracted at 24, 48, and 72 h p.t. RNA
was quantified by qPCR, and quantification of rRNA was used for normalization. Values are numbers of HCV genome copies per 50 ng of total
RNA and are averages from at least three independent experiments. Error bars indicate standard deviations.
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this case, reversal of these mutations was observed upon inoc-
ulation in the uPA-SCID mouse model (50).Therefore, RNA
sequences contained in the core region are cis-acting elements
important but not essential for RNA replication. In line with
this notion, both the Luc-nocore-NS3 and the Luc-nocore-NS2
RNA constructs replicated efficiently in cell culture. Despite
efficient RNA replication, however, the former construct was
also efficiently trans-packaged, while the latter was not trans-
packaged or was trans-packaged at very low efficiency. The only
difference between these two constructs is the presence of NS2
in Luc-nocore-NS2. Thus, in this particular context, the pres-
ence of NS2 appears to hinder the ability of a subgenomic
HCV RNA to be efficiently trans-packaged by the wt helper
virus. Interestingly, however, the impairment due to the pres-
FIG. 10. Efficiency of infection and replication in naïve Huh-7.5 or clone 9 cells of subgenomic deletion mutants packaged in naïve Huh-7.5 or
clone 9 cells. Supernatants of transfections at 48 h p.t. from the experiment described in the legend to Fig. 9 were used to infect either naïve
Huh-7.5 (A) or clone 9 (B) cells. Total cellular RNA was extracted at 24, 48, and 72 h postinfection. RNA quantification was performed by qPCR.
Quantification of rRNA was used for normalization. Values are numbers of HCV genome copies per 50 ng of total RNA and are averages from
at least three independent experiments. Error bars indicate standard deviations.
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ence of NS2 was rescued by the presence of core, pointing to
an important cross talk between these two viral genes.
A similar conclusion could be drawn from a comparison of
the monocistronic constructs containing core region: Luc-
core212-NS2 and Luc-core212-NS3. The former was repli-
cation and trans-packaging competent, while the latter was
totally impaired, confirming that the presence or absence of
NS2 makes the difference.
Consistent with our finding, the genomic region in addition
to core that is almost always maintained in natural subgenomic
deletion mutants is NS2 and, in particular, its catalytic domain.
In fact, NS2 plays a critical function in the processing of the
NS2/NS3 junction (24, 53), and the correct NS3 N terminus is
absolutely necessary for HCV replication (19). Thus, it is con-
ceivable that it may be extremely difficult to obtain a precise
boundary at the NS3 N terminus by whatever natural mecha-
nism leads to the generation of internal deletions in vivo (e.g.,
recombination). Therefore, the presence of a catalytically ac-
tive NS2 protease domain guarantees a precise cleavage of the
NS2/NS3 junction and offers some flexibility at the 3 recom-
bination point, locating it almost anywhere between E1-E2 and
the end of the trans-membrane NS2 domain. It is notable that
in both the NS3-NS5B replicon and in the Luc-nocore-NS3
construct reported here (both without core and NS2 regions
and, nevertheless, efficiently trans-packaged), the correct NS3
N terminus is obtained via the encephalomyocarditis virus
(EMCV) IRES and via the presence of a UBI monomer,
respectively. In addition, although NS2 has been demonstrated
to be dispensable for replication, it is essential for virus pro-
duction even independently of its protease activity (18, 19, 40),
likely playing some important structural role. Altogether, these
experiments further confirm the strict positive relationship of
core and NS2 in both replication and trans-packaging effi-
ciency. The precise nature of this interplay has yet to be elu-
cidated, but important core/NS2 direct or indirect interactions
have also been implied by the observation that an alanine-
scanning mutant in core (amino acids 69 to 72) could be effi-
ciently rescued for virus production by an NS2-A880P com-
pensating mutation (34).
In summary, we speculate that the specific genome regions
core and NS2 must be maintained for the efficient replication
and trans-packaging of natural subgenomes. NS2 at least is
necessary for the correct determination of the NS3 N terminus
and its presence, for an efficient trans-packaging, requires the
presence of the core region.
trans-complementation of HCV proteins has been demon-
strated in vitro in a few cases for both structural and nonstruc-
tural proteins. The latter have been extensively investigated
with the HCV replicon system, and the only protein that can be
provided in trans is NS5A (2, 48). trans-complementation of
core has been demonstrated with a 17- to 163-amino-acid core
deletion in JFH-1 which is complemented and trans-packaged
by a core-expressing DNA plasmid (32). trans-complementa-
tion of larger structural protein deletions has been demon-
strated with JFH-1 by Jones et al. and, more recently, by
Steinmann and coworkers (19, 46). In the work of Jones et al.,
two JFH-1 luciferase constructs, one with E1-E2 deleted (iden-
tical deletion to our J6/JFH-E1E2) and the other in p7, both
replication competent, were cotransfected into Huh-7.5 cells
with the rescue of virus production. A more extensive study
was performed by Steinmann and coworkers in which both
helper viruses and a stable cell line were utilized for comple-
mentation in trans (46). Although in overall agreement with
their results, the study presented here reveals some discrepan-
cies.
When wt JFH-1 was cotransfected together with either Luc-
E1E2 (an IRES-luc-JFH-1E1E2 construct) or Luc-NS3-5B
(an IRES-luc-NS3/5B replicon construct), the latter was pack-
aged much more efficiently than the former (46). In contrast,
we found that in similar cotransfection experiments, with wt
J6/JFH as the helper, J6/JFH-E1E2 is trans-packaged with an
efficiency similar to or better than that of the JFH-neo-rep
construct (Fig. 4). This might be explained by the different
structure of the packaged genomes. It is known that Luc-
E1/E2 replicates with substantially delayed kinetics com-
pared to JFH-1 (25). More likely, as discussed above with
regard to the boundaries of natural subgenomic deletions, the
deletion of important core RNA sequences might be detrimen-
tal to trans-packaging efficiency.
Steinmann et al. generated a stable cell line expressing
core-E1 and E2-p7-NS2 from two distinct genetic units (46).
This packaging cell line was able to trans-complement both a
p7 deletion of JFH-1 (Jc1p7) and a Luc replicon (Luc-SG),
although the former was much more efficient than the latter
(about 10-fold).
Using our core-NS2 expression plasmid, we were unable to
achieve efficient trans-packaging of any of the subgenomic de-
letion mutants we investigated, including the JFH-1 replicon.
This discrepancy may be due to the different genetic organi-
zation of packaging cell lines: two genetic units (separately
encoding core-E1 and E2-p7-NS2) as opposed to a single RNA
messenger encoding core-NS2 proteins, in our case processed
from a common polyprotein precursor. The fact that core-NS2
polyprotein could be correctly processed and topologically ori-
ented in cells is demonstrated by the finding that inserting the
EMCV IRES between NS2 and NS3 did not interfere with
RNA replication and reduced infectivity titers only very mod-
erately (19).
It is tempting to speculate that our core-NS2 expression
vector might generate structural proteins that might not easily
be available for trans-packaging. In DNA-RNA cotransfections
with subgenomic J6/JFH-284-736 (which contains a wt NS2),
the removal of either core or NS2 from the core-NS2 expres-
sion vector restores the capacity for trans-complementation
(Fig. 8). In the first case, E1-E2-p7-NS2 could not be targeted
independently to lipid droplets due to the absence of core (32).
In the second case, that of core-E1-E2-p7, the lack of NS2
might play an important role.
Upon analysis of these trans-complementation experiments,
one might speculate that NS2 participates in two independent
complexes: one that includes structural proteins (NS2 plus
core-E1-E2-p7) and one that includes NS3-NS5B/RNA (NS2
plus replication complex). These complexes probably have dif-
ferent localizations: around lipid droplets for the former and
diffusely on the ER membranes for the latter (32). Once these
two complexes are separately formed, they cannot interact to
assemble a virus. When NS2 is removed from any of these
complexes (or the removal of core affects assembly complex
formation or lipid droplet localization), the reciprocal interac-
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tion is restored. NS2 might behave as an exclusive alternative
bridge between these two complexes.
It is conceivable that replication of such subgenomes in the
hepatocyte in the absence of coinfection by wt virus could lead
to an abnormal accumulation of core proteins in lipid droplets
inside the host cells, as demonstrated in vitro with genomes
that are poorly packaged (42). It would be interesting to study
in detail whether core protein accumulation as a consequence
of the efficient replication of these subgenomes and the lack of
egress of virus could influence and contribute to liver patho-
genesis during the progression of HCV-associated chronic
hepatitis.
In conclusion, we have studied the in vitro behavior of two
representative in-frame subgenomic deletion mutants found
circulating in patients. The study of natural subgenomic dele-
tion mutants, as opposed to artificial constructs generated in
laboratories, gives us the unique opportunity to study the HCV
life cycle with a wider range of physiological reagents and
provides insight into the requirements of HCV for survival in
vivo. This is a significant step forward in comparison with other
studies of trans-packaging performed so far, confirming the
hypotheses that naturally occurring deletion-containing HCV
genomes can be competent for replication and packaged into
infectious virions by coexistence with wt virus. In addition, we
have found that the boundaries of the natural subgenomic
deletions correspond to precise requirements for efficient rep-
lication and trans-packaging. We have established trans-pack-
aging protein requirements as well as a trans-packaging and
infectious cell line capable of mimicking the effect of wt virus
coinfection. In addition, the variety of structural proteins pro-
vided for trans-packaging has highlighted important features
that might help dissect the interaction of the replication com-
plex with structural proteins, and this will form the basis of
future studies.
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